We and others have shown the feasibility of eIF4A inhibitors against a range of cancers including leukemia, non-Hodgkin’s lymphoma—especially MYC+/BCL2+ lymphomas, and perhaps more modestly against pancreatic cancer [21,34,35]. The gene discussed is BCL2; the disease is non-Hodgkin lymphoma.